Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
Teerlink
John R
JR
Heart Failure Clinic, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, School of Medicine, San Francisco, Calif 94121-1545, USA. johnt@itsa.ucsf.edu
D000208:Acute Disease; D017277:Drug Approval; D004417:Dyspnea / Q000188:drug therapy* / Q000503:physiopathology; D005544:Forecasting; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D045283:Natriuretic Agents / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain; D011724:Pyridazines / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D000077464:Simendan; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D006835:Hydrazones; D045283:Natriuretic Agents; D011724:Pyridazines; D011725:Pyridines; D013777:Tetrazoles; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; C120582:tezosentan